Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a ...
A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along ...
ctDNA offers a minimally invasive alternative for detecting PIK3CA, AKT1, and PTEN alterations in hormone receptor-positive breast cancer when tissue is unavailable. The CAPItello-291 trial showed ...
Liquid biopsy using ctDNA refines risk stratification for patients with residual cancer burden post-neoadjuvant therapy, ...
Patients with stage 3 colorectal cancer who tested MRD-positive with Signatera after surgery saw a meaningful survival ...
Personalis publishes a new study in Clinical Cancer Research to monitor cancer immunotherapy response across solid tumours: Fremont, California Friday, December 19, 2025, 16:00 Hr ...
News-Medical.Net on MSN
Blood test identifies colon cancer patients who benefit from anti-inflammatory medication
A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along ...
In this interview, Dr. Gary Pestano and Dr. Prithwish Pal discuss the advantages ddPCR offers in molecular residual disease ...
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that data utilizing its RaDaR ® 1.0 assay for the detection of ...
Data include findings generated using the RaDaR 1.0 assay to assess molecular residual disease and recurrence risk in early breast cancer NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback